Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Vaccination of immunocompromised adults
Infectious diseases, microbiology and sexual health · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Time-critical presentation
Do not administer a live vaccine to a person with significant current immunosuppression unless a specialist and the current Green Book explicitly support it. Treat suspected vaccine anaphylaxis immediately with intramuscular adrenaline and ABCDE care.
Role and principles
Plan safe, timed and effective vaccination for adults with altered immunity by defining the immune defect, separating live from non-live vaccines and coordinating doses with immunosuppressive treatment.
The vaccination decision has three components: what protection the patient needs, whether the product is live, and when the immune system can respond safely. Diagnosis labels are insufficient. Establish treatment name, dose and timing, transplant status, current lymphocyte or immune recovery where relevant, previous infection and complete vaccine history.
Non-live vaccines are commonly given during immunosuppression when disease risk is high, while accepting that response may be reduced and later revaccination might be recommended. Live vaccines require a much higher threshold because attenuated organisms can disseminate. The Green Book and responsible specialist determine contraindication and the interval before or after therapy.
Plans should survive care transitions. Record exact products and dates, future doses, whether a course must be restarted or continued, and who owns recall. Provide advice on post-exposure contact because passive immunisation or antiviral treatment may be time critical even when vaccination was attempted.
Key points
Define why immunity is altered: malignancy, transplantation, biological therapy, corticosteroid exposure, HIV, asplenia and primary immune deficiency create different vaccine restrictions and expected responses.
Assessment and patient selection
Profound treatment-related immunosuppressionRed flag
Recent chemotherapy, stem-cell or solid-organ transplantation, B-cell-depleting therapy and intensive combination immunosuppression markedly alter vaccine safety, timing and response.
Live-vaccine requestRed flag
MMR, varicella and several travel vaccines contain live organisms and require explicit immune-status assessment before administration.
Risk-based vaccine gap
Absent influenza, COVID-19, pneumococcal, shingles or other indicated protection is common when records are fragmented across primary and specialist care.
Post-exposure urgencyRed flag
Contact with measles, varicella, hepatitis B or another vaccine-preventable infection may require immunoglobulin, antiviral treatment or accelerated vaccination through a specialist pathway.
Establish product, date, dose number and documented reaction across primary, hospital and patient-held records.
Interpretation and limitations
Do not assume a generic code proves a complete course. Missing information should trigger record retrieval and a risk-based plan rather than automatic repetition of live vaccines.
02Immune treatment timeline
Why
Determine when suppression begins, peaks and recovers and whether planned vaccination would delay essential therapy.
Interpretation and limitations
Use the exact medicine and protocol with the prescribing specialist; drug classes differ, and B-cell depletion can impair responses long after the last dose.
03Current Green Book risk schedule
Why
Identify national product, interval, booster and contraindication recommendations for the patient's condition.
Interpretation and limitations
Schedules are updated and differ by age, diagnosis and previous doses. Use the live chapter rather than a remembered table.
04Targeted immune or serological assessment
Why
Answer a specific question about immune recovery or protection when specialist guidance recommends testing.
Interventions
01Before planned treatmentUse the pre-immunosuppression windowFirst stepImmunosuppressive therapy is planned and there is time to improve protection safely.+
1Reconcile vaccines and infection history, define the regimen and planned start date and identify risk-based and routine gaps using current Green Book chapters.
2Give indicated non-live and specialist-approved live vaccines at the required interval before therapy, without delaying urgent cancer or immune treatment inappropriately.
3Document incomplete courses, future revaccination, response limitations and post-exposure instructions for primary and specialist care.
02During immune suppressionPrioritise safe non-live protectionThe patient is currently receiving treatment that alters vaccine response or contraindicates live products.+
1Confirm current intensity and recovery expectations with the responsible specialist and exclude live vaccination unless a current expert pathway explicitly permits it.
Medicines and treatment safety
Reduces influenza and secondary complication risk without live-virus replication.
Inactivated influenza vaccine
Give the current programme-recommended intramuscular adult product and schedule each influenza season for the eligible risk group.
Check previous anaphylaxis, current acute illness and programme product choice; immune response may be attenuated and vaccination does not exclude influenza in a symptomatic patient.
Prevents shingles using a non-live vaccine suitable for many immunocompromised groups.
Recombinant zoster vaccine
Give the current Green Book risk-based two-dose intramuscular schedule, using the interval specified for immunocompromised adults.
Verify age, diagnosis, previous doses and current programme eligibility; local reactions are common, and timing should be coordinated with immune treatment when feasible.
Targets, monitoring and follow-up
Maintain an exact vaccine and treatment timeline with product, batch where recorded, site, date, next dose and named owner for recall.
Observe after vaccination according to setting and history, with immediate anaphylaxis equipment and trained staff available.
Review local and systemic adverse effects and report suspected serious reactions through the MHRA Yellow Card scheme.
Reassess vaccine needs after transplant, immune reconstitution, splenectomy or a major treatment change because previous protection may no longer be adequate.
Document post-exposure contacts and outcomes, including passive immunisation, antivirals and any planned later vaccination.
Special situations
Safe does not mean effective
A non-live vaccine may be safe during treatment yet produce a weaker response; timing and later revaccination remain clinically important.
Live is a product property
Do not infer that every vaccine for one disease is live or non-live; check the exact product and current programme.
Serology has limits
A detectable antibody does not always equal complete protection, and a negative result does not measure all immune memory.
Contacts form a protective ring
Routine household vaccination reduces exposure, but advice is needed after selected live vaccines when the patient is profoundly immunocompromised.
Common pitfalls
01
Giving a live vaccine from an outdated memory of the patient's treatment status.
02
Delaying urgent immunosuppressive therapy solely to complete a routine vaccine course.
03
Recording 'up to date' without product and dose dates.
04
Assuming non-live vaccination during profound suppression guarantees protection.
05
Forgetting time-critical post-exposure prophylaxis because the patient previously received a vaccine.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Infectious diseases, microbiology and sexual healthOriginal SBA
Live vaccine during treatment
An adult receiving intensive combination immunosuppression asks for a live travel vaccine before departure next week. What is the safest next step?
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Non-live vaccines cannot cause infection from replication and are generally safe, but responses may be weaker during profound immunosuppression; timing should maximise benefit without delaying essential treatment.
Live vaccines may replicate and cause disease in significant immunosuppression. Check the current Green Book, product information and specialist plan before administration.
Vaccinate before planned immunosuppression when feasible, respecting the minimum interval required between a live vaccine and treatment; never improvise an interval from memory.
Reconcile product, date and dose number rather than recording only 'vaccinated'. Risk-based influenza, COVID-19, pneumococcal, shingles and other schedules change over time.
Household contacts should receive routine vaccines, with specific advice around selected live products, because reducing exposure can indirectly protect the immunocompromised person.
Vaccination does not remove the need for early assessment of fever, antimicrobial prophylaxis when indicated or post-exposure treatment for diseases such as measles, varicella or hepatitis B.
Interpretation and limitations
Routine antibody panels are not a universal measure of vaccine protection. Some assays lack an accepted protective threshold or do not measure cellular immunity.
05Travel and exposure assessment
Why
Identify destination-specific live vaccines, outbreak risk and limited access to urgent care.
Interpretation and limitations
Refer early to a travel-medicine or infection specialist when a live travel vaccine is contraindicated and exemption, itinerary change or alternative prevention is needed.
2Offer indicated non-live vaccines when benefit exceeds reduced-response concerns, using programme-specific products and intervals.
3Arrange later doses or revaccination where guidance recommends, and reinforce infection, household-contact and exposure advice.
03After exposureDo not rely on prior vaccination aloneA significantly immunocompromised adult has meaningful contact with a vaccine-preventable infection.+
1Verify exposure timing, infectious period, immune diagnosis, vaccine record and symptoms and contact infection or health-protection specialists immediately.
2Use pathogen-specific post-exposure vaccination, immunoglobulin or antiviral treatment within the recommended window and isolate or exclude as advised.
3Provide symptom monitoring and an emergency route, document the exposure and update the longer-term vaccination plan after the event.